banner
 
bar

program

bar
 
 

iQ&A interactive
Medical Intelligence Zone for
Familial Hypercholesterolemia

pre-program survey
We Invite You to Take a Moment and Complete This
Pre-Program Knowledge and Clinical Performance Survey.
Thank You

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium

Internet-based program

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period April 30, 2012 through April 30, 2014, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 74 segments, totaling 2 hours and 36 minutes, to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate.

Estimated Time to Complete Educational Activity

2.5 hours

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in the management of familial hypercholesterolemia.

Release Date

April 30, 2012

Expiration Date

April 30, 2014

Intended Audience

This complimentary CME educational activity is designed for all healthcare providers (HCPs) involved in developing, delivering, consulting, and monitoring care for patients with familial hypercholesterolemia.

This constituency of HCPs shall include the following audience:

  • Cardiologists
  • Atherosclerosis experts
  • Lipidologists
  • Thrombosis medicine specialists
  • Preventive medicine specialists
  • Pediatric cardiovascular specialists
  • Endocrine and cardiometabolic disease specialists
  • Cardiology department program directors
  • Clinical geneticists
  • Clinical cardiovascular pharmacists
  • Related specialists

Registration

Participation in this iQ&A interactive Medical Intelligence Zone for Familial Hypercholeterolemia is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

logoSupported by an educational grant from Genzyme.

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School Office of Continuing Medical Education (UMMS-OCME) and CMEducation Resources, LLC. The UMMS-OCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Massachusetts Medical School designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosure

Christie M. Ballantyne, MD
Director, Center for Cardiovascular Disease Prevention
Methodist DeBakey Heart Center
Chief of the Section of Cardiovascular Research
Baylor College of Medicine
Director of Atherosclerosis Laboratory
Professor of Medicine
Baylor College of Medicine
Houston, TX

Advisor or Consultant: Abbott Laboratories; Amarin Corporation plc; Adnexus; Amylin Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Esperion Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Idera Pharmaceuticals Inc.; Kowa Company Ltd.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Omthera Pharmaceuticals, Inc.; Resverlogix Corp; Roche; sanofi-aventis; Synthelabo; Takeda Pharmaceuticals North America, Inc.
Speaker or Speakers Bureau: Abbott Laboratories; GlaxoSmithKline; Merck & Co., Inc.


William Boden, MD

Chief of Medicine
Albany (NY) Stratton VA Medical Center
Vice Chair, Department of Medicine
Albany Medical Center
Albany, NY

Speaker: Abbott, Gilead, sanofi-aventis


Robin Choudhury, MD

Wellcome Trust Senior Research Fellow
University of Oxford
Consultant Cardiologist
John Radcliffe Hospital
Oxford Acute Vascular Imaging Centre
Oxford, England

Consultant: Roche, sanofi-aventis, AstraZeneca
Speaker: Merck
Research Support: Merck, Novartis


Michael Davidson, MD, FACC, FNLA

Director of Preventive Cardiology
Clinical Professor of Medicine
University of Chicago Pritzker School of Medicine
Executive Medical Director
Radiant Research
Chicago, IL

Advisory Board/Consultant: Amgen, Merck, Roche, Sanofi-aventis
Stockholder: Omthera Pharmaceuticals


James De Lemos, MD

Associate Professor of Medicine
Sweetheart Ball-Kern Wildenthal, MD, PhD Distinguished Chair in Cardiology
University of Texas, Southwestern Medical School
Director, Coronary Care Unit
Parkland Memorial Hospital
Director, Cardiology Fellowship
University of Texas Southwestern Medical School
Dallas, Texas

Speaker: Bristol-Myers Squibb, sanofi-aventis
Consultant: AstraZeneca


Mary McGowan, MD

Medical Director
Cholesterol Treatment Center
Concord Hospital Cholesterol Treatment Center
Concord, NH
Assistant Professor of Medicine
University of Massachusetts Medical Center

Consultant: Genzyme, Amgen, sanofi-aventis
Speaker: GlaxoSmithKline, Merck


Prof. Dr. Heribert Schunkert, MD

Professor of Internal Medicine and Cardiology
Director of Medizinische Klinik II
Universitätsklinikum Schleswig-Holstein
Campus Lübeck, Germany

Nothing to disclose


Professor Erik Stroes, MD

Chair of the Department of Vascular Medicine
Academic Medical Center in Amsterdam
Amsterdam, The Netherlands

Nothing to disclose


Allen J. Taylor, MD, FACC, FAHA

Director, Advanced Imaging
Washington Hospital Center
Professor of Medicine
Washington, DC

Speaker: Abbott Laboratories


Sotirios Tsimikas, MD, FACC, FAHA, FSCAI

Professor of Medicine
Director of Vascular Medicine
University of Calfornia, San Diego School of Medicine
San Diego, CA

Consultant: Isis Pharmaceuticals, Inc.; Genzyme Corporation; sanofi-aventis; Amarin Corporation plc
Speaker: Merck & Co., Inc.
Research Support: Pfizer Inc; Merck & Co., Inc.
Stock, stock options, or bonds: Atherotope

Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewer Denise Leary has nothing to disclose.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Apply the Simon Broome Register criteria to confirm the diagnosis of heterozygous familial hypercholesterolemia (HeFH);
  • Determine the LDL-C target goals for patients with HeFH, based on a number of criteria and consensus recommendations including risk categories and/or maximally attainable LDLC reductions;
  • Understand the clinical implications of the underlying genetic mutations, including LDLR and APOB mutations, that underpin impaired LDL receptor function or LDL removal in patients with HeFH;
  • Employ currently available, statin-based treatment regimens to achieve LDL-C target goals for HeFH, and be able to act upon the indications and clinical triggers for more aggressive LDLC lowering in high risk patients
  • Understand the molecular mechanisms of action (MOA) and potential clinical implications of novel, antisense oligonucleotides (ASOs) as therapeutic agents that may be used instead of, or in combination with, traditional lipid-lowering agents in CVD and hypercholesterolemic patients; and, especially in patients carrying inherited disorders of lipoprotein metabolism, including FH, FDB, ARH, mutations in the PCSK9 gene, sitosterolemia, cholesterol 7α-hydroxylase deficiency and polygenic hypercholesterolemia;
  • Deploy ASOs in patients with inherited lipoproteins disorders, based on a scientific understanding of their efficacy on LDL-C reduction as compared to traditional statins, their pharmacokinetic and pharmacodynamics profiles, metabolism, side effects, drug-drug interactions, usefulness in statin-intolerant patients, and clinical triggers for their deployment as adjunctive therapy in hypercholesterolemia;
  • Apply the results, conclusions, and findings of landmark clinical trials evaluating the safety and efficacy of ASOs for optimizing target goal attainment in patients with FH;
  • Understand the clinical rationale and metabolic implications of targeting specific lipid moieties, such as apolipoprotein B-100 (apoB-100), the major protein moiety of the atherogenic lipoproteins LDL and Lp(a), as the ideal target for antisense therapy;
  • Detail a scientifically rigorous, mechanistically and clinically relevant understanding of ASOs, and the metabolic effects that result when short, single-stranded synthetic analogs of nucleic acids that bind to a target mRNA, preventing its translation and thereby inhibiting protein synthesis, and the potential application of such MOAs to treatment of patients with FH;

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Copyright © 2012 by Pharmatecture, LLC and CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

pre-program survey
We Invite You to Take a Moment and Complete This
Pre-Program Knowledge and Clinical Performance Survey.
Thank You

bar

program

bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © CMEducation Resources, LLC and Pharmatecture, LLC

 
6

 

Key Program Topics Include:

ACT
alemtuzumab
Avonex
Axonal
Azathioprine
Behçet
BENEFIT
betaseron
BEYOND
Brain Atrophy
brain stem
CD4+ T
cerebellum,
spinal cord
cerebral cortex
Cladribine
CHAMPIONS
CHAMPS/ETOMS

Copaxone
Corticosteroids
Cyclophosphamide
daclizumab
Demyelination
DMD
EDSS
EVIDENCE
Fingolimod
Glatiramer acetate
HIV
HTLV-1
Human IgG4IFN b-1a
IFN b-1b
Immunosuppression
Laquinimod
INCOMIN

Interferon
Lesions
Lyme disease
Methotrexate
Mitoxantrone
MRI
Multiple Sclerosis
relapsing-remitting MS
Mycophenolate mofetil
Natalizumab
neuritic transection
neurodegenerative
Neuroimmunomodulating
neuroimmunomodulation
Neurosyphilis
NIMO
NMSS
Novantrone

optic nerves
periventricular
PML
PRECISE
PRISMS
Rebif
REGARD
rituximab
RRMS
Sarcoidosis
Selective adhesion molecule inhibitor
Sjögren syndrome
Statins
Teriflunomide
Tysabri
white matter